Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational trial with rigosertib in patients with RDEB-associated squamous cell carcinoma

Trial Profile

A registrational trial with rigosertib in patients with RDEB-associated squamous cell carcinoma

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 02 Apr 2024 According to a Onconova Therapeutics media release, Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
  • 16 Aug 2023 New trial record
  • 10 Aug 2023 According to an Onconova Therapeutics media release, based on a constructive Type B FDA meeting held in June, the company has planned to design this registrational trial and will look to provide an update on next steps in H1 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top